|
Gene: ZNF208 |
Gene summary for ZNF208 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ZNF208 | Gene ID | 7757 |
Gene name | zinc finger protein 208 | |
Gene Alias | PMIDP | |
Cytomap | 19p12 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | M0QYK4 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7757 | ZNF208 | HCC1 | Human | Liver | HCC | 2.90e-08 | 2.82e+00 | 0.5336 |
7757 | ZNF208 | HCC2 | Human | Liver | HCC | 2.94e-26 | 3.97e+00 | 0.5341 |
7757 | ZNF208 | male-WTA | Human | Thyroid | PTC | 2.12e-07 | 1.42e-01 | 0.1037 |
7757 | ZNF208 | PTC01 | Human | Thyroid | PTC | 2.09e-04 | 1.40e-01 | 0.1899 |
7757 | ZNF208 | PTC04 | Human | Thyroid | PTC | 1.04e-12 | 2.83e-01 | 0.1927 |
7757 | ZNF208 | PTC05 | Human | Thyroid | PTC | 6.87e-11 | 4.08e-01 | 0.2065 |
7757 | ZNF208 | PTC06 | Human | Thyroid | PTC | 2.67e-27 | 6.23e-01 | 0.2057 |
7757 | ZNF208 | PTC07 | Human | Thyroid | PTC | 1.67e-30 | 4.95e-01 | 0.2044 |
7757 | ZNF208 | ATC13 | Human | Thyroid | ATC | 9.45e-20 | 4.74e-01 | 0.34 |
7757 | ZNF208 | ATC5 | Human | Thyroid | ATC | 3.64e-23 | 5.14e-01 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
ZNF208 | END | Thyroid | Healthy | HES5,MIR181A1HG,PIM2, etc. | 2.38e-01 |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF208 | SNV | Missense_Mutation | novel | c.3805N>T | p.Ser1269Cys | p.S1269C | O43345 | protein_coding | deleterious(0.04) | possibly_damaging(0.9) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
ZNF208 | SNV | Missense_Mutation | c.3830N>C | p.Gly1277Ala | p.G1277A | O43345 | protein_coding | tolerated(0.06) | benign(0.178) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
ZNF208 | SNV | Missense_Mutation | novel | c.2696N>T | p.Ser899Ile | p.S899I | O43345 | protein_coding | tolerated(0.26) | benign(0.013) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ZNF208 | SNV | Missense_Mutation | c.3516N>C | p.Glu1172Asp | p.E1172D | O43345 | protein_coding | tolerated(0.45) | possibly_damaging(0.832) | TCGA-A2-A25D-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
ZNF208 | SNV | Missense_Mutation | novel | c.2670N>C | p.Lys890Asn | p.K890N | O43345 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-A7-A2KD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
ZNF208 | SNV | Missense_Mutation | c.2152N>C | p.Glu718Gln | p.E718Q | O43345 | protein_coding | deleterious(0.02) | probably_damaging(0.993) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ZNF208 | SNV | Missense_Mutation | c.592N>C | p.Glu198Gln | p.E198Q | O43345 | protein_coding | tolerated(0.08) | possibly_damaging(0.471) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ZNF208 | SNV | Missense_Mutation | novel | c.3514N>C | p.Glu1172Gln | p.E1172Q | O43345 | protein_coding | tolerated(0.36) | possibly_damaging(0.884) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ZNF208 | SNV | Missense_Mutation | c.1136N>G | p.Lys379Arg | p.K379R | O43345 | protein_coding | tolerated(0.63) | benign(0.239) | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |
ZNF208 | SNV | Missense_Mutation | novel | c.2363N>C | p.Arg788Pro | p.R788P | O43345 | protein_coding | tolerated(0.13) | benign(0.429) | TCGA-AQ-A7U7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | rituximab | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |